Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sangamo Therapeutics, Inc. (SGMO : OTC)

• Company Description    Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $0.17 Daily Weekly Monthly 20 Day Moving Average: 18,669,312 shares Shares Outstanding: 414.28 (millions) Market Capitalization: $72.21 (millions) Beta: 1.04 52 Week High: $0.77 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.65% -34.99% 12 Week -60.39% -63.38% Year To Date -58.50% -65.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 501 Canal Blvd - Richmond,CA 94804 USA ph: 510-970-6000 fax: 510-236-8951 ir@sangamo.com http://www.sangamo.com

• General Corporate Information    Officers Alexander D. Macrae - President; Chief Executive Officer H. Stewart Parker - Director and Chair of the Board Nikunj Jain - Interim Chief Financial Officer Courtney Beers - Director Robert F. Carey - Director Peer Information Sangamo Therapeutics, Inc. (CORR.) Sangamo Therapeutics, Inc. (RSPI) Sangamo Therapeutics, Inc. (CGXP) Sangamo Therapeutics, Inc. (BGEN) Sangamo Therapeutics, Inc. (GTBP) Sangamo Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 800677106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 414.28 Most Recent Split Date: 6.00 (1.25:1) Beta: 1.04 Market Capitalization: $72.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.09 EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -77.60% vs. Previous Quarter: -89.87% ROE 03/31/26 - - 12/31/25 - -2,662.06 09/30/25 - -813.95 ROA 03/31/26 - -143.96 12/31/25 - -132.12 09/30/25 - -116.48 Current Ratio 03/31/26 - 0.70 12/31/25 - 0.84 09/30/25 - 0.88 Quick Ratio 03/31/26 - 0.70 12/31/25 - 0.84 09/30/25 - 0.88 Operating Margin 03/31/26 - -318.59 12/31/25 - -277.35 09/30/25 - -331.28 Net Margin 03/31/26 - -356.89 12/31/25 - -310.81 09/30/25 - -331.28 Pre-Tax Margin 03/31/26 - -358.88 12/31/25 - -312.25 09/30/25 - -332.63 Book Value 03/31/26 - -0.05 12/31/25 - -0.04 09/30/25 - 0.02 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00

Powered by Zacks Investment Research ©